Cambrian is a drug research and distribution company. With a mission to develop curative therapies for age-related diseases, Cambrian is partnering with clinical development researchers to help treat cellular dysfunction and tissue degeneration. Some programs included in the Cambrian pipeline include Telos Biotech, Tornado Therapeutics, and Amplifier Therapeutics. Cambrian was founded by Christian Angermayer, James Peyer, and Sebastian Brunemeier in 2019 and is headquartered in New York, New York.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
10/26/2021 | Series C | $100.78MM | $xx.xx | $486.23MM | Anthos Capital, Apeiron Investment Group, Future Ventures, Moore Capital, Salt Fund | |
Price per Share
$xx.xx
Shares Outstanding
14,500,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Anthos Capital, Apeiron Investment Group, Future Ventures, Moore Capital, Salt Fund
|
||||||
02/09/2021 | Series B | $28.83MM | $xx.xx | $181.45MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
9,300,995
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
11/15/2019 | Series A | $15.5MM | $xx.xx | $58.68MM | Njf Capital | |
Price per Share
$xx.xx
Shares Outstanding
12,400,000
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Njf Capital
|
||||||
10/29/2019 | Series Seed | $4.75MM | $xx.xx | $11.88MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
13,419,027
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|